Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–26 of 26 results
Advanced filters: Author: Chris Boshoff Clear advanced filters

  • With the first wave of cancer immunotherapies continuing to show their potential to revolutionize treatment paradigms, major pharmaceutical companies are leaving no stone unturned in the search for winning combination therapies that harness immuno-oncology drugs.

    • Chris Morrison
    News
    Biopharma Dealmakers

  • Kaposi's sarcoma–associated herpesvirus is a major oncogenic virus that has been implicated in human cancers. A new study identifies ephrin receptor A2 as a key host receptor for this virus that permits infection of endothelial cells (pages 961–966).

    • Chris Boshoff
    News & Views
    Nature Medicine
    Volume: 18, P: 861-863

  • The bifunctional enzyme CoaBC catalyses the second and third step in the Coenzyme A (CoA) biosynthesis pathway and is of interest as a M. tuberculosis drug target. Here, the authors present the full-length crystal structure of Mycobacterium smegmatis CoaBC, which is regulated by CoA and CoA thioesters and forms a dodecamer and by performing a high-throughput screen they identify selective inhibitors of M. tuberculosis CoaB that bind to an allosteric site within CoaB.

    • Vitor Mendes
    • Simon R. Green
    • Tom L. Blundell
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-12

  • “The disease leads to death, and it does so within a short period of two to three years...The disease must, from our present experience, be considered from the onset not only as incurable but also as deadly.”—Moritz Kaposi, 1872

    • Chris Boshoff
    News & Views
    Nature Medicine
    Volume: 9, P: 262

  • Kaposi sarcoma-associated herpesvirus (KSHV) is involved in the etiopathogenesis of Kaposi sarcoma and certain lymphoproliferative disorders. Open reading frame (ORF) 73 encodes the main immunogenic latent nuclear antigen (LNA-1) of KSHV. LNA-1 maintains the KSHV episome and tethers the viral genome to chromatin during mitosis. In addition, LNA-1 interacts with p53 and represses its transcriptional activity. Here we show that LNA-1 also interacts with the retinoblastoma protein. LNA-1 transactivated an artificial promoter carrying the cell cycle transcription factor E2F DNA-binding sequences and also upregulated the cyclin E (CCNE1) promoter, but not the B-myb (MYBL2) promoter. LNA-1 overcame the flat-cell phenotype induced by retinoblastoma protein in Saos2 cells. In cooperation with the cellular oncogene Harvey rat sarcoma viral oncogene homolog (Hras), LNA-1 transformed primary rat embryo fibroblasts and rendered them tumorigenic. These findings indicate that LNA-1 acts as a transcription co-factor and may contribute to KSHV-induced oncogenesis by targeting the retinoblastoma protein–E2F transcriptional regulatory pathway

    • Stoyan A. Radkov
    • Paul Kellam
    • Chris Boshoff
    Research
    Nature Medicine
    Volume: 6, P: 1121-1127

  • Kaposi sarcoma herpesvirus (KSHV) seems to exploit almost every known cancer pathway to promote tumorigenesis. Activation of the canonical Wnt–β-catenin pathway can now be added to its list of conquests (pages 300–306).

    • Chris Boshoff
    News & Views
    Nature Medicine
    Volume: 9, P: 261-262

  • Kaposi's sarcoma (KS) is the most common cancer in HIV-infected untreated individuals. Kaposi's sarcoma-associated herpesvirus (KSHV) is the infectious cause of KS. This Review discusses the insights into the remarkable mechanisms through which KSHV can induce KS that have been gained in the past 15 years.

    • Enrique A. Mesri
    • Ethel Cesarman
    • Chris Boshoff
    Reviews
    Nature Reviews Cancer
    Volume: 10, P: 707-719

  • Kaposi's sarcoma-associated herpesvirus has been detected in every Kaposi's sarcoma biopsy, yet nobody knows how the virus contributes to the tumour-cell formation that is associated with the disease. The key, it now seems, may lie with the so-called G-protein-coupled receptor. This protein is encoded by the virus, and it induces the production of a powerful factor that stimulates the formation of blood vessels to nourish the tumour cells.

    • Chris Boshoff
    News & Views
    Nature
    Volume: 391, P: 24-25

  • Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.

    • Holden T Maecker
    • J Philip McCoy Jr
    • Jung-Hua Yeh
    Comments & Opinion
    Nature Immunology
    Volume: 11, P: 975-978

  • Peter Campbell and colleagues identify PLCG1 and PTPRB as new driver genes for angiosarcoma through whole-exome sequencing of tumor samples. They find somatic PTPRB mutations in 10 of 39 cases and PLCG1 mutations in 3 of 34 cases, along with mutations in known cancer-related genes.

    • Sam Behjati
    • Patrick S Tarpey
    • Peter J Campbell
    Research
    Nature Genetics
    Volume: 46, P: 376-379